Recent Quotes
My Watchlist
Indicators
Star 60
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Dr. Reddy's Laboratories Ltd Common Stock (NY:RDY)

13.22 -0.09 (-0.68%)
Streaming Delayed Price Updated: 1:03 PM EDT, Apr 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Dr. Reddy's Laboratories Ltd Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Dr. Reddy’s to Acquire Nicotinell and Related Portfolio in Significant Step Towards Building Global Consumer Healthcare Business
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Aurigene Pharmaceutical Services Limited, a Global CRDMO, Announces the Opening of Its Biologics Facility Offering Process Development and Clinical Scale Manufacturing Capabilities
From Aurigene Pharmaceutical Services Ltd.
Via Business Wire
News headline image
Dr Reddy's Laboratories: Q3 Earnings Insights ↗
 
Via Benzinga
News headline image
Is NYSE:RDY suited for quality investing? ↗
Exploring DR. REDDY'S LABORATORIES-ADR (NYSE:RDY)'s quality characteristics. 
Via Chartmill
News headline image
India Stocks Rally On Modi Election Wave. This Indian Bank Stock Hits High. ↗
Exit polls forecast a landslide win and third consecutive term for Prime Minister Narendra Modi in India's general elections. 
Via Investor's Business Daily
News headline image
Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America
From Dr. Reddy's Laboratories Ltd.
Via Business Wire
News headline image
Alvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Should you consider NYSE:RDY for quality investing? ↗
DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) may be suited for quality investing, we'll explore why in this article. 
Via Chartmill
News headline image
Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK
From Alvotech
Via GlobeNewswire
News headline image
RDY Stock Earnings: Dr Reddy’s Laboratories Beats EPS, Misses Revenue for Q4 2024 ↗
RDY stock results show that Dr Reddy's Laboratories beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2024. 
Via InvestorPlace
News headline image
Dr. Reddy’s Q4 & Full Year FY24 Financial Results
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Chart Of The Day: What's Cooking At Dr. Reddy's Lab ↗
100% technical buy signals 12 new highs and up 10.76% in the last month 38.40+ Weighted Alpha 
Via Talk Markets
News headline image
Dr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S.
From Dr. Reddy's Laboratories Ltd.
Via Business Wire
News headline image
Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Global Access to Weight-Loss Treatments: Indian Pharma Giants Eye Affordable Wegovy Alternatives Amid Rising Demand ↗
Indian pharmaceutical giants, including Sun Pharma and Cipla, seize the opportunity to develop affordable versions of Novo Nordisk's Wegovy weight-loss treatment. With patents set to expire by... 
Via Benzinga
Topics Intellectual Property
News headline image
Dr. Reddy’s Q3 & 9M FY24 Financial Results
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Dr. Reddy's Announces the Acquisition of MenoLabs®, a Leading Women’s Health and Dietary Supplements Portfolio of Brands
From Dr. Reddy's Laboratories Ltd.
Via Business Wire
News headline image
Dr. Reddy’s becomes first Indian pharma company to debut on the Dow Jones Sustainability World Index
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Coya Therapeutics, Inc. and Dr. Reddy’s Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS)
From Coya Therapeutics, Inc.
Via Business Wire
News headline image
2 overlooked stocks that crushed earnings but traded lower
As the third quarter 2023 earnings season ends, it's worth looking back to see which stocks may have been overlooked or mispriced on their results 
Via MarketBeat
News headline image
Dr. Reddy’s Q2 FY24 Financial Results
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Why Quality Investors Should Delve into DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) for Investment Opportunities. ↗
Reasonable Growth, Debt Levels, and a High ROIC Make DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) Appealing to Quality Investors. 
Via Chartmill
News headline image
Top 5 Health Care Stocks That May Fall Off A Cliff ↗
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
News headline image
Dr. Reddy's Laboratories Announces its Launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S.
From Dr. Reddy's Laboratories Ltd.
Via Business Wire
News headline image
Dr. Reddy’s Q1 FY24 Financial Results
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Dr. Reddy’s Proposed Rituximab Biosimilar Application Accepted for Review by USFDA, EMA and MHRA
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Why Are Journey Medical Shares Trading Lower Today? ↗
Journey Medical Corporation (NASDAQ: DERM) shares are trading lower after the company announced topline results from the two Phase 3 trials, evaluating Minocycline Hydrochloride Modified Release... 
Via Benzinga
News headline image
Drugmaker GSK: Becoming a Healthier Value Stock
Up more than 25% in the last nine months, U.K. pharmaceutical company GSK PLC is slowly regaining favor with investors after the GSK lawsuit. 
Via MarketBeat
Topics Lawsuit
News headline image
Why Are Journey Medical Shares Trading Higher Today ↗
Journey Medical Corporation (NASDAQ: DERM) announced topline data from the Phase 1 clinical trial assessing the impact of DFD-29 on the  
Via Benzinga
News headline image
Dr. Reddy’s Successfully Completes Phase I Study (IV Route) of DRL_TC, a Proposed Biosimilar of Tocilizumab
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.